2nd Quarter - Report — TERUMO BCT, INC. for TERUMO BCT, INC. (2026)

Firm

TERUMO BCT, INC.

Client

TERUMO BCT, INC.

Income

—

Expenses

$20,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Global trade and tariffs

Lobbyist	Covered position, as disclosed
LATOYA THOMAS	—

Contacted: HOUSE OF REPRESENTATIVES

Health Issues HCR

S.735/H.R. 1796 - Reauthorization of Sickle Cell Disease and Other Heritable Blood Disorders Research, Blood and cell collection, storage, and processing Blood donation supply and quality

Lobbyist	Covered position, as disclosed
LATOYA THOMAS	—

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Bills named: S. 735 (119th), H.R. 1796 (119th)

Medicare/Medicaid MMM

Medicaid Eligibility, work and community engagement requirements

Lobbyist	Covered position, as disclosed
LATOYA THOMAS	—

Contacted: Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.